FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210343019> ?p ?o ?g. }

• W4210343019 endingPage "1657" @default.
• W4210343019 startingPage "1649" @default.
• W4210343019 abstract "In recent years, there has been increasing evidence supporting the role of germline pharmacogenomic factors predicting toxicity for anticancer therapies. Although somatic genomic data are used frequently in oncology care planning, germline pharmacogenomic testing is not. This study hypothesizes that comprehensive germline pharmacogenomic profiling could have high relevance for cancer care.Between January 2011 and August 2020, patients at the University of Chicago Medical Center were genotyped across custom germline pharmacogenomic panels for reasons unrelated to cancer care. Actionable anticancer pharmacogenomic gene/drug interactions identified by the FDA were defined including: CYP2C9 (erdafitinib), CYP2D6 (gefitinib), DPYD (5-fluorouracil and capecitabine), TPMT (thioguanine and mercaptopurine), and UGT1A1 (belinostat, irinotecan, nilotinib, pazopanib, and sacituzumab-govitecan hziy). The primary objective was to determine the frequency of individuals with actionable or high-risk genotypes across these 5 key pharmacogenes, thus potentially impacting prescribing for at least 1 of these 11 commonly prescribed anticancer therapies.Data from a total of 1586 genotyped individuals were analyzed. The oncology pharmacogene with the highest prevalence of high-risk, actionable genotypes was UGT1A1, impacting 17% of genotyped individuals. Actionable TPMT and DPYD genotypes were found in 9% and 4% of patients, respectively. Overall, nearly one-third of patients genotyped across all 5 genes (161/525, 31%) had at least one actionable genotype.These data suggest that germline pharmacogenomic testing for 5 key pharmacogenes could identify a substantial proportion of patients at risk with standard dosing, an estimated impact similar to that of somatic genomic profiling.Differences in our genes may explain why some drugs work safely in certain individuals but can cause side effects in others. Pharmacogenomics is the study of how genetic variations affect an individual's response to medications. In this study, an evaluation was done for important genetic variations that can affect the tolerability of anticancer therapy. By analyzing the genetic results of >1500 patients, it was found that nearly one-third have genetic variations that could alter recommendations of what drug, or how much of, an anticancer therapy they should be given. Performing pharmacogenomic testing before prescribing could help to guide personalized oncology care." @default.
• W4210343019 created "2022-02-08" @default.
• W4210343019 creator A5011720511 @default.
• W4210343019 creator A5018398274 @default.
• W4210343019 creator A5023528057 @default.
• W4210343019 creator A5038171309 @default.
• W4210343019 creator A5049759474 @default.
• W4210343019 creator A5058852670 @default.
• W4210343019 creator A5068268371 @default.
• W4210343019 creator A5070939740 @default.
• W4210343019 creator A5082814338 @default.
• W4210343019 creator A5091328328 @default.
• W4210343019 date "2022-01-28" @default.
• W4210343019 modified "2023-10-16" @default.
• W4210343019 title "Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing" @default.
• W4210343019 cites W1965504402 @default.
• W4210343019 cites W1969692023 @default.
• W4210343019 cites W1979235563 @default.
• W4210343019 cites W1989314574 @default.
• W4210343019 cites W2008883952 @default.
• W4210343019 cites W2014398845 @default.
• W4210343019 cites W2091091750 @default.
• W4210343019 cites W2095822339 @default.
• W4210343019 cites W2100636598 @default.
• W4210343019 cites W2105786255 @default.
• W4210343019 cites W2116957273 @default.
• W4210343019 cites W2138509705 @default.
• W4210343019 cites W2174633205 @default.
• W4210343019 cites W2191975304 @default.
• W4210343019 cites W2590645692 @default.
• W4210343019 cites W2603897434 @default.
• W4210343019 cites W2753565653 @default.
• W4210343019 cites W2762997972 @default.
• W4210343019 cites W2770862842 @default.
• W4210343019 cites W2800172156 @default.
• W4210343019 cites W2896913847 @default.
• W4210343019 cites W2900673338 @default.
• W4210343019 cites W2901027936 @default.
• W4210343019 cites W2906827613 @default.
• W4210343019 cites W2921564361 @default.
• W4210343019 cites W2972796741 @default.
• W4210343019 cites W2985960711 @default.
• W4210343019 cites W2990707203 @default.
• W4210343019 cites W3006072391 @default.
• W4210343019 cites W3009686858 @default.
• W4210343019 cites W3012167797 @default.
• W4210343019 cites W3014558303 @default.
• W4210343019 cites W3080458669 @default.
• W4210343019 cites W3110956748 @default.
• W4210343019 cites W3119005666 @default.
• W4210343019 cites W3121793515 @default.
• W4210343019 cites W3133328851 @default.
• W4210343019 cites W3167955109 @default.
• W4210343019 cites W3178094080 @default.
• W4210343019 doi "https://doi.org/10.1002/cncr.34104" @default.
• W4210343019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35090043" @default.
• W4210343019 hasPublicationYear "2022" @default.
• W4210343019 type Work @default.
• W4210343019 citedByCount "3" @default.
• W4210343019 countsByYear W42103430192023 @default.
• W4210343019 crossrefType "journal-article" @default.
• W4210343019 hasAuthorship W4210343019A5011720511 @default.
• W4210343019 hasAuthorship W4210343019A5018398274 @default.
• W4210343019 hasAuthorship W4210343019A5023528057 @default.
• W4210343019 hasAuthorship W4210343019A5038171309 @default.
• W4210343019 hasAuthorship W4210343019A5049759474 @default.
• W4210343019 hasAuthorship W4210343019A5058852670 @default.
• W4210343019 hasAuthorship W4210343019A5068268371 @default.
• W4210343019 hasAuthorship W4210343019A5070939740 @default.
• W4210343019 hasAuthorship W4210343019A5082814338 @default.
• W4210343019 hasAuthorship W4210343019A5091328328 @default.
• W4210343019 hasBestOaLocation W42103430191 @default.
• W4210343019 hasConcept C104317684 @default.
• W4210343019 hasConcept C109825262 @default.
• W4210343019 hasConcept C121608353 @default.
• W4210343019 hasConcept C126322002 @default.
• W4210343019 hasConcept C135763542 @default.
• W4210343019 hasConcept C143998085 @default.
• W4210343019 hasConcept C170734499 @default.
• W4210343019 hasConcept C2778260677 @default.
• W4210343019 hasConcept C2778439243 @default.
• W4210343019 hasConcept C2779134260 @default.
• W4210343019 hasConcept C2779490328 @default.
• W4210343019 hasConcept C2779655350 @default.
• W4210343019 hasConcept C54355233 @default.
• W4210343019 hasConcept C55775858 @default.
• W4210343019 hasConcept C60644358 @default.
• W4210343019 hasConcept C70917649 @default.
• W4210343019 hasConcept C71924100 @default.
• W4210343019 hasConcept C86803240 @default.
• W4210343019 hasConcept C98274493 @default.
• W4210343019 hasConceptScore W4210343019C104317684 @default.
• W4210343019 hasConceptScore W4210343019C109825262 @default.
• W4210343019 hasConceptScore W4210343019C121608353 @default.
• W4210343019 hasConceptScore W4210343019C126322002 @default.
• W4210343019 hasConceptScore W4210343019C135763542 @default.
• W4210343019 hasConceptScore W4210343019C143998085 @default.
• W4210343019 hasConceptScore W4210343019C170734499 @default.

• next